CAI Form 4: J. Russel Denton purchases 4,184 shares

Q: What insider transaction was reported for CAI?

J. Russel Denton purchased 4,184 shares of Caris Life Sciences common stock.

Q: When did the CAI insider purchase occur?

The transaction date was 11/07/2025 .

Q: What was the price for the CAI insider purchase?

A $24.09 weighted average, with trades ranging from $23.99 to $24.15 .

Q: How many CAI shares does the insider own after the trade?

Beneficial ownership is 9,184 shares indirectly by trust and 123,591 shares directly.

Q: What is the insider’s role at CAI?

Senior Vice President, General Counsel, and Secretary .

Filing Impact

(Moderate)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Caris Life Sciences (CAI) reported an insider purchase on a Form 4. J. Russel Denton, Senior Vice President, General Counsel, and Secretary, bought 4,184 shares of common stock on 11/07/2025 at a weighted average price of $24.09, with trades executed between $23.99 and $24.15.

After this transaction, he beneficially owns 9,184 shares indirectly by trust and 123,591 shares directly. The price range note indicates multiple trade executions aggregated into the reported average.

Insider Trade Summary

Net Buyer: 4,184 shares

Net Buy 2 txns

Insider Denton John Russel

Role See Remarks

Bought 4,184 shs ($101K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	4,184	$24.09	$101K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 9,184 shares (Indirect, By Trust); Common Stock — 123,591 shares (Direct)

Footnotes (1)

F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.99 to $24.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/10/2025 - 08:12 AM

FAQ

What insider transaction was reported for CAI?

J. Russel Denton purchased 4,184 shares of Caris Life Sciences common stock.

When did the CAI insider purchase occur?

The transaction date was 11/07/2025.

What was the price for the CAI insider purchase?

A $24.09 weighted average, with trades ranging from $23.99 to $24.15.

How many CAI shares does the insider own after the trade?

Beneficial ownership is 9,184 shares indirectly by trust and 123,591 shares directly.

What is the insider’s role at CAI?

Senior Vice President, General Counsel, and Secretary.

What SEC form disclosed this CAI transaction?

It was disclosed on a Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Denton John Russel

(Last)

(First)

(Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING

75039

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/07/2025		P		4,184	A	$24.09⁽¹⁾	9,184	I	By Trust
Common Stock								123,591	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.99 to $24.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Senior Vice President, General Counsel, and Secretary

	/s/ J. Russel Denton	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR